Evaluation of c-myc proto-oncogene in primary human breast carcinomas - PubMed (original) (raw)
Comparative Study
. 1991 Jul-Aug;11(4):1421-7.
Affiliations
- PMID: 1660688
Comparative Study
Evaluation of c-myc proto-oncogene in primary human breast carcinomas
Z P Pavelic et al. Anticancer Res. 1991 Jul-Aug.
Abstract
The expression of the c-myc proto-oncogene product was examined by immunohistochemistry in 11 normal breast tissues, 31 invasive and 14 non-invasive breast carcinomas. The c-myc product was detected in all breast carcinoma specimens and in seven of 11 normal breast tissues. Invasive tumors stained more frequently with the anti-myc monoclonal antibody (MAb) than non-invasive tumors, while the level of expression in normal breast tissue was much less than that in a breast cancer. Marked heterogeneity in the c-myc expression was seen among different tumors and within individual tumors. None of the eight invasive tumors with a high protein level of the c-myc showed evidence of gene amplification by Southern blot analysis.
Similar articles
- Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y, Hashimoto T, Matsubara F, Yanaihara N. Mizukami Y, et al. Anticancer Res. 1991 Jul-Aug;11(4):1485-94. Anticancer Res. 1991. PMID: 1660689 - c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma.
Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA, Preisler HD. Pavelic ZP, et al. Cancer Res. 1992 May 1;52(9):2597-602. Cancer Res. 1992. PMID: 1348967 - The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
Lavialle C, Modjtahedi N, Lamonerie T, Frebourg T, Landin RM, Fossar N, Lhomond G, Cassingena R, Brison O. Lavialle C, et al. Anticancer Res. 1989 Sep-Oct;9(5):1265-79. Anticancer Res. 1989. PMID: 2686529 Review.
Cited by
- Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Sovak MA, et al. J Clin Invest. 1997 Dec 15;100(12):2952-60. doi: 10.1172/JCI119848. J Clin Invest. 1997. PMID: 9399940 Free PMC article. - Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA. Dueck AC, et al. Clin Cancer Res. 2013 Oct 15;19(20):5798-807. doi: 10.1158/1078-0432.CCR-13-0558. Epub 2013 Aug 21. Clin Cancer Res. 2013. PMID: 23965903 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical